Scleritis and other ocular side effects associated with pamidronate disodium
- PMID: 12566027
- DOI: 10.1016/s0002-9394(02)01840-8
Scleritis and other ocular side effects associated with pamidronate disodium
Abstract
Purpose: To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis.
Design: Observational case series.
Methods: Case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute), the Food and Drug Administration, the World Health Organization, and the literature were reviewed to determine possible adverse ocular side effects associated with pamidronate disodium. The World Health Organization's Causality Assessment Guide was used to categorize an adverse drug reaction.
Results: Seventeen cases of unilateral scleritis and one case of bilateral scleritis occurred, usually within 6 hours to 2 days after intravenous pamidronate disodium. Six patients had positive rechallenge testing with the scleritis occurring after a repeat drug exposure. Other ocular side effects with positive rechallenge data, associated with pamidronate disodium, include blurred vision, nonspecific conjunctivitis, ocular pain, bilateral anterior uveitis, and episcleritis.
Conclusions: This is the first report, with rechallenge data, of any drug causing scleritis. Pamidronate disodium can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis.
Similar articles
-
Pamidronate disodium and possible ocular adverse drug reactions.Am J Ophthalmol. 1994 Aug 15;118(2):220-4. doi: 10.1016/s0002-9394(14)72902-2. Am J Ophthalmol. 1994. PMID: 8053468
-
Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.Bull Soc Belge Ophtalmol. 2003;(290):71-6. Bull Soc Belge Ophtalmol. 2003. PMID: 14750233
-
Drug-induced ocular inflammatory diseases.Drugs Today (Barc). 2007 Feb;43(2):117-23. doi: 10.1358/dot.2007.43.2.1050789. Drugs Today (Barc). 2007. PMID: 17353948 Review.
-
Anterior uveitis and diffuse scleritis after pamidronate infusion.CMAJ. 2023 Dec 17;195(49):E1722. doi: 10.1503/cmaj.230859. CMAJ. 2023. PMID: 38110218 Free PMC article. No abstract available.
-
Ocular Side Effects of Bisphosphonates: A Review of Literature.J Ocul Pharmacol Ther. 2023 Jan-Feb;39(1):3-16. doi: 10.1089/jop.2022.0094. Epub 2022 Nov 21. J Ocul Pharmacol Ther. 2023. PMID: 36409537 Review.
Cited by
-
Ocular adverse effects associated with systemic medications : recognition and management.Drugs. 2007;67(1):75-93. doi: 10.2165/00003495-200767010-00006. Drugs. 2007. PMID: 17209665 Review.
-
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.Osteoporos Int. 2005 Dec;16(12):1989-98. doi: 10.1007/s00198-005-1986-1. Epub 2005 Aug 31. Osteoporos Int. 2005. PMID: 16133643
-
Safety of long-term bisphosphonate therapy for the management of osteoporosis.Drugs. 2011 Apr 16;71(6):791-814. doi: 10.2165/11585470-000000000-00000. Drugs. 2011. PMID: 21504254 Review.
-
Drug-induced uveitis.J Ophthalmic Inflamm Infect. 2013 Mar 25;3(1):43. doi: 10.1186/1869-5760-3-43. J Ophthalmic Inflamm Infect. 2013. PMID: 23522744 Free PMC article.
-
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.Osteoporos Int. 2012 Feb;23 Suppl 1(Suppl 1):S1-23. doi: 10.1007/s00198-011-1891-8. Epub 2012 Feb 4. Osteoporos Int. 2012. PMID: 22311111 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical